ClinicalTrials.gg
Status unknownNCT05130021Updated Dec 6, 2021

A Clincal Study of Max-40279-01 in Patients With Advanced Colorectal Cancer

A Phase 2 interventional study of MAX-40279-01 and regorafenib in Metastatic Colorectal Cancer, sponsored by Maxinovel Pty., Ltd.. Status unknown at 1 site in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-12-06.

Sponsored by Maxinovel Pty., Ltd. · Phase 2, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2021), so the status shown — last known as Not yet recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
130
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 59 studies testing regorafenib in Colorectal Neoplasms — 10 open to participants now, 15 under way, 3 of them phase 3. regorafenib · Colorectal Neoplasms.

Planned enrollment
13th of 58
130 · median 55
Started
2022
with 2 others
Phase 2
29 of 59
5 open now
Registered
46th of 59
by date

Among the 59 studies testing regorafenib in Colorectal Neoplasms, this one is the 13th largest by planned enrollment of the 58 interventional ones that give a count, is one of 3 that started in 2022, is one of 29 in phase 2, and was the 46th registered.

Colorectal Neoplasms

6,552 studies on the registry are indexed under Colorectal Neoplasms; 1,664 are open to participants now.

Browse Colorectal Neoplasms studies →

Open to participants now

10 of the 59 studies testing regorafenib in Colorectal Neoplasms are open now, in 4 countries. Recruiting first, the newest first:

5 more — sign in →

By country, each count listing its studies:

All 10 open studies →

About regorafenib

regorafenib: first FDA approval 2012 (STIVARGA), first EMA approval 2013. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,178 Colorectal Neoplasms studies recruiting now, 761 (65%) set no upper age limit and 264 (22%) stop at 75 or younger; 48 take children under 18; 123 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 59 studies testing regorafenib in Colorectal Neoplasms, or all of them as a file.
02

Study summary

This include two parts, part 1 is a dose optimizing study and part 2 is a randomized, controlled study.

Read the detailed description

This study is a study of Max-40279-01 in patients with advanced colorectal cancer. This study include two Parts, the Part 1 will assess the safety and efficacy of the preset two dose level of Max-40279-01, and recommend a dose level of Max-40279-01 for stage 2. The part 2 is a randomized, controlled study ,and designed to compare the efficacy and safety of max-40279-01 to regorafenib or best support care(BSC) in pretreated advanced colorectal cancer.

03

Conditions studied

  • Metastatic Colorectal Cancer

Keywords

  • metastatic colorectal cancer
  • pretreated
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Males and/or females over age 18
  2. and/or cytologically documented local advanced or colorectal adenocarcinoma.
  3. (ECOG) performance status of 0-1.
  4. Expected survival >3 months.
  5. previously treated with standard, approved therapies, including two (fluoropyrimidine,oxaliplatin and irinotecan based), a biological VEGF inhibitor, and, if RAS wild-type, an EGFR inhibitor. Patients with MSI-H/MMR-deficient tumors also must have received an , if available and approved. In addition, patients with BRAF mutant tumors must also have received a BRAF inhibitor, if available and approved.
  6. Signed form.

Exclusion criteria

Exclusion Criteria:

  1. Known uncontrolled or symptomatic central nervous system disease.
  2. Adverse events (with exception of alopecia, peripheral sensory neuropathy grade ≤ 2 and those listed in specific exclusion criteria) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [] v.3.0) at the time of randomization.
  3. Inadequate organ or bone marrow function.
  4. Medical history of difficulty swallowing, malabsorption or other chronic gastrointestinal disease, or conditions that may hamper compliance and/or absorption of the tested product.
  5. Pregnant or breast-feeding woman.
  6. Known allergies, , or intolerance to Max-40279-01 the of these treatments The above information was not intended to contain all considerations relevant to a participant's potential participation in a clinical trial.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
130 participants (estimated)

Study arms

  • Experimental
    Part 1;50mg

    Drug: MAX-40279-01

  • Experimental
    Part 1;70mg

    Drug: MAX-40279-01

  • Experimental
    Part 2;MAX-40279-01

    Drug: MAX-40279-01

  • Experimental
    Part 2;regorafenib

    Drug: regorafenib

Interventions

06

What researchers measure

Primary outcomes

  1. Disease control rate (DCR)[Part 1]

    Time frame: Through study Part 1 completion, an average of 6 months

  2. progress free survival(PFS)[Part 2]

    Time frame: Through study Part 1 completion, an average of 6 months

Secondary outcomes

  1. Tmax

    Time to maximum plasma concentration

    Time frame: Approximately 6 months

  2. Cmax

    Maximum plasma drug concentration

    Time frame: Approximately 6 months

  3. AUC

    Area under the time-concentration curve

    Time frame: Approximately 6 months

  4. Objective response rate (ORR)

    Time frame: 6 months (anticipated)

  5. overall survival (OS)

    Time frame: 24 months

  6. Safety and tolerability assessed by incidence and severity of adverse events

    Time frame: 24 months

07

Study locations

1 site
  • The Sixth Affiliated Hospital of Sun Yat-sen University
    Guangzhou, Guangdong, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jan 2022; primary completion for May 2022, 3 months later.

Of 120 industry-sponsored phase 2 interventional studies under Colorectal Neoplasms, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 72. This study's planned 3 months is below that.

Counting every sponsor, half of 618 studies reached it within 49 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2021
First posted
Nov 22, 2021
StartEst.
Jan 31, 2022
Primary completionEst.
May 30, 2022
CompletionEst.
Oct 31, 2023
Last update
Dec 6, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 6, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05130021
Lead sponsor
Maxinovel Pty., Ltd.
Responsible party
Sponsor
First posted
Nov 22, 2021
Start date
Jan 31, 2022 (estimated)
Primary completion
May 30, 2022 (estimated)
Completion
Oct 31, 2023 (estimated)
Last update
Dec 6, 2021

Study contacts

Hanying Bao, MD,Ph.D
Contact
hybao@maxinovel.com
+86-021-51370693
Yanhong Y Deng, Dr
Contact
13925106525@163.com
+8613925106525

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Nefextinib · Regorafenib

Start the discussion